Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 11/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336674 | 0.88 | TAAR1 (0.46) | AOC3ESR1ESR2 | |
| SCHEMBL6337298 | 0.87 | ESR2 (0.53) | ESR1ESR2 | |
| SCHEMBL6343463 | 0.80 | ESR2 (0.69) | ESR1ESR2 | |
| SCHEMBL6337297 | 0.79 | ESR2 (0.52) | ESR1ESR2 | |
| SCHEMBL6340932 | 0.79 | ESR2 (0.60) | ESR1ESR2 | |
| SCHEMBL8506218 | 0.78 | ESR1 (0.41) | ESR1ESR2 | |
| SCHEMBL8507343 | 0.78 | AOC3 (0.47) | AOC3ESR1ESR2CHRM1KCNH2 | |
| SCHEMBL6337734 | 0.77 | ESR2 (0.50) | AOC3ESR1ESR2 | |
| SCHEMBL9367154 | 0.77 | ALDH1A1 (0.36) | — | |
| SCHEMBL6339546 | 0.75 | ESR2 (0.56) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943162-B2 | Osteoporosis; cardiovascular disorders; anticancer agents;incontinence | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040072829-A1 | Piperazinyltriazines as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072829-A1 | Piperazinyltriazines as estrogen receptor modulators | GPER1, ESR2, ESR1 | AOC3 2580/4885ESR1 3/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.